May 30 - June 03, 2025; Chicago, Illinois and Virtual
ASCO 2025
Marathon Runners May Have Higher Colon Cancer Risk
ASCO 2025
The Power of Choice in Cancer Care: Why It Matters
ASCO 2025
MCED Screening: What Patients Need to Know
ASCO 2025
Does Elinzanetant Reduce VMS in Younger Patients?
ASCO 2025
Sexual Effects Persist After Cervical Cancer Treatment
ASCO 2025
Q&A: New Myeloma Bispecific Rivals CAR T in Early Data
ASCO 2025
Asciminib: High Responses in Second-Line Chronic-Phase CML
ASCO 2025
Myeloma: OBI Rivals IV Isatuximab, Ups Patient Comfort
ASCO 2025
HL: Second-Line Sintilimab Plus Chemo Bests Chemo Alone
ASCO 2025
Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy
ASCO 2025
Nivolumab Plus Chemotherapy Improves Survival in Lung Cancer
ASCO 2025
IRONMAN: Can PSA Guide Metastatic Prostate Cancer Care?
ASCO 2025
Emerging Treatment Strategies Benefit Older Adults With ALL
ASCO 2025
OS Data From CARTITUDE-1: A Cure for Myeloma?
ASCO 2025
Can a TKI Boost Anti-PD-L1 Activity in NSCLC?
ASCO 2025
Can New Combo Fill ‘Unmet Need’ in R/R Hodgkin Lymphoma?
ASCO 2025
Niraparib May Slow Hormone-Sensitive Mets Prostate Cancer
ASCO 2025
Which Tx Combo Is Best for HER2+ Breast Cancer?
ASCO 2025
Surgery Before or After Chemo for Advanced Ovarian Cancer?
ASCO 2025
PVEK: New Standard of Care in Rare, Deadly Blood Cancer?
ASCO 2025
Could Liquid Biopsy Guide Treatment in Cervical Cancer?
ASCO 2025
Luspatercept May Prolong Life in Low-Risk MDS
ASCO 2025
Durvalumab Plus FLOT Improves Early Upper-GI Cancer
ASCO 2025
Catching Resistance Early: Can New Breast Cancer Drug Help?
ASCO 2025
Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRC
ASCO 2025
Rusfertide: First Self-Injected Drug to Cut Phlebotomy
ASCO 2025
Can Lifestyle Changes Save Lives in Colon Cancer?
ASCO 2025
Atezolizumab + Chemo Improves Colon Cancer Survival
ASCO 2025
Relacorilant + Nab-Paclitaxel Beneficial in Ovarian Cancer
ASCO 2025
Adjuvant Nivolumab + CRT Improves DFS in HNSCC
ASCO 2025
Tumor Treating Fields Boost Pancreatic Cancer Survival
ASCO 2025
In Pancreatic Cancer, Does New PAXG Beat Out mFOLFIRINOX?
ASCO 2025
Can New Biomarker Help Identify High-Risk DLBCL Patients?
ASCO 2025
Which Class of ER Degrader Is Better?
ASCO 2025
CAR T-Cell Therapy Boosts PFS in Advanced Gastric Cancer
ASCO 2025
Ph+ALL: Post-Induction, Ponatinib Yields Molecular Response
ASCO 2025
Sacituzumab or Chemo in First-Line TNBC: Which Is Better?
ASCO 2025
Can GLP-1s Protect Against Obesity-Related Cancers?
ASCO 2025
Adding Lurbinectedin Shows Benefit in SCLC
ASCO 2025
Benefits Persist With Inavolisib in Breast Cancer
Medscape Oncology©
ASCO 2025: Melanoma Oral Abstracts Emphasize Trial Limits
ASCO 2025: Melanoma TILs, Toxicity, and Diet Insights
Adaptive Communication Matters in Oncology Care
Emerging Themes in GI Oncology from ASCO 2025
Evolving Approaches in Melanoma Treatment
Exercise Intervention Boosts Colon Cancer Survival Benefits
Breast Cancer Recap: Inavolisib, PROTACs, ADCs in Focus
Early Breast Cancer Highlights From ASCO 2025
Prostate Cancer Highlights From ASCO 2025
Metastatic Breast Cancer Highlights From ASCO 2025
ASCO 2025: Reshaping the Landscape in Endometrial Cancer
Integrating ASCO 2025 Insights in Early-Stage Breast Cancer
Clinical Advances in Multiple Myeloma From ASCO 2025
Lymphoma Highlights From ASCO 2025
ASCO 2025: Impact of Therapeutic Advances in Prostate Cancer
Updates in Metastatic NSCLC From ASCO 2025
Key Abstracts in Early-Stage NSCLC From ASCO 2025
ASCO 2025: New Standards Reshape Care in mBC
EGFR+ NSCLC: Experts Weigh Risk vs Reward at ASCO 2025
Key Highlights in Ovarian Cancer From ASCO 2025
ASCO 2025: Clinical Impact of New Data in Advanced NSCLC
Teamwork in Oncology Spotlighted at ASCO
ASCO 2025: Key Highlights in Endometrial and Related Cancers
ASCO 2025: Key Highlights in Metastatic Breast Cancer
ASCO 2025: Key Highlights in Advanced Lung Cancer
ASCO 2025: Key Updates in Early Breast Cancer Care
ASCO 2025: Highlights in Prostate Cancer Biomarkers and Therapies
ASCO 2025: A Preview of Advancements in Endometrial Cancer
ASCO 2025: Previewing Key Updates in Metastatic Breast Cancer
ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC
ASCO 2025: Previewing Updates in Early-Stage Breast Cancer
ASCO 2025: Anticipating Key Innovations in Prostate Cancer
